In 2017, over two decades since FLT3 mutations were first described in AML, midostaurin gained US Food and Drug Administration (FDA) approval, becoming first agent to achieve FDA approval for AML since the year 2000. This evidence concerns the gene FLT3 and acute myeloid leukemia.